Zocor (simvastatin) and Lipitor (atorvastatin) are both statin drugs, which are medications used to lower cholesterol levels in the blood. Statins primarily work by inhibiting the enzyme HMG-CoA ...

BofA analyst Jason Gerberry lowered the firm’s price target on Organon (OGN) to $10 from $11 and keeps an Underperform rating on the shares.The firm said the company cutting its dividend was a ...

Organon (OGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Organon (OGN) reported $1.51 billion in revenue for the quarter ended March 2025, representing a year-over-year decline of 6.7%. EPS of $1.02 for the same period compares to $1.22 a year ago.